Boston Scientific (BSX) has just been removed from several Russell growth benchmarks, including the Russell 1000 Growth and Russell Top 200 Growth indexes. This change may affect index-linked ownership and trading interest.

The index removals come after a tough stretch for Boston Scientific's stock, with the share price at $43.06 and share price returns declining 10.25% over 30 days and 54.53% year to date, while the 1 year total shareholder return has fallen 58.45%. This suggests momentum has been fading despite recent product and investment news.

If this kind of index and healthcare news has you rethinking your watchlist, it might be a good moment to scout other medical technology opportunities through our screener of 39 healthcare AI stocks.

With Boston Scientific now trading well below many analysts’ price targets after steep recent declines, the key question for investors is simple: is this weakness pointing to undervaluation, or is the market already pricing in future growth?

Most Popular Narrative: 56.5% Undervalued

Against the last close at $43.06, the most followed Boston Scientific narrative points to a fair value of $98.90, creating a wide gap for investors to assess.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:
* Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.

Want to see why this narrative still points to a much higher value for Boston Scientific? The core assumptions mix faster earnings growth, expanding margins, and a richer future earnings multiple. Curious which combination of revenue expansion and profitability shifts has the biggest impact on that $98.90 figure? The full storyline unpacks how those moving parts fit together.

Result: Fair Value of $98.90 (UNDERVALUED)

However, Boston Scientific’s narrative could be challenged if the Penumbra integration delivers weaker cost or revenue benefits, or if higher leverage limits future flexibility.

Next Steps

With sentiment around Boston Scientific clearly split, this is a good time to review the facts yourself and decide how compelling the upside really looks. To see what is driving optimism in the data, take a closer look at the 4 key rewards

Looking for more investment ideas beyond Boston Scientific?

If the Boston Scientific story has you rethinking where to focus next, do not sit on the sidelines while other opportunities line up on your radar.

• Target potential mispriced opportunities by scanning companies highlighted in our 41 high quality undervalued stocks.
• Secure more dependable income streams by checking out stocks in the 8 dividend fortresses.
• Dial down risk while staying invested by reviewing companies in the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.